CLLS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Cellectis SA

NASDAQ | CLLS

3.90

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 14, 2025)

$376.66M

Market Cap

-

P/E Ratio

-0.33

EPS

$5.48

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

CLLS Chart

Recent Chart
Price Action

CLLS Technicals

Tags:

CLLS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $32M
Total Revenue $42M
Cost Of Revenue $9.2M
Costof Goods And Services Sold $9.2M
Operating Income -$60M
Selling General And Administrative $8.4M
Research And Development $91M
Operating Expenses $92M
Investment Income Net -
Net Interest Income $3.8M
Interest Income $11M
Interest Expense $7.5M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $20M
Income Before Tax -$37M
Income Tax Expense -$6.4M
Interest And Debt Expense -
Net Income From Continuing Operations -$37M
Comprehensive Income Net Of Tax -
Ebit -$29M
Ebitda -$9.5M
Net Income -$37M

Revenue & Profitability

Earnings Performance

CLLS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $384M
Total Current Assets $287M
Cash And Cash Equivalents At Carrying Value $143M
Cash And Short Term Investments $143M
Inventory -
Current Net Receivables $23M
Total Non Current Assets $96M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.1M
Intangible Assets Excluding Goodwill $1.1M
Goodwill -
Investments -
Long Term Investments $7.5M
Short Term Investments $117M
Other Current Assets $3.7M
Other Non Current Assets -
Total Liabilities $253M
Total Current Liabilities $166M
Current Accounts Payable $19M
Deferred Revenue -
Current Debt -
Short Term Debt $13M
Total Non Current Liabilities $95M
Capital Lease Obligations $43M
Long Term Debt $44M
Current Long Term Debt $4.8M
Long Term Debt Noncurrent -
Short Long Term Debt Total $91M
Other Current Liabilities $22M
Other Non Current Liabilities $882K
Total Shareholder Equity $131M
Treasury Stock -
Retained Earnings -$330M
Common Stock $5.9M
Common Stock Shares Outstanding $91M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $22M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $20M
Capital Expenditures $2.6M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$103M
Cashflow From Financing $90M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $0
Dividend Payout Common Stock $0
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$37M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $32M
Total Revenue $42M
Cost Of Revenue $9.2M
Costof Goods And Services Sold $9.2M
Operating Income -$60M
Selling General And Administrative $8.4M
Research And Development $91M
Operating Expenses $92M
Investment Income Net -
Net Interest Income $3.8M
Interest Income $11M
Interest Expense $7.5M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $20M
Income Before Tax -$37M
Income Tax Expense -$6.4M
Interest And Debt Expense -
Net Income From Continuing Operations -$37M
Comprehensive Income Net Of Tax -
Ebit -$29M
Ebitda -$9.5M
Net Income -$37M

CLLS News

CLLS Profile

Cellectis SA Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Cellectis SA is a clinical-stage biotechnology company based in Paris, France, focused on pioneering immuno-oncology therapies through its innovative gene-editing platform. The firm specializes in developing T cell therapies that utilize chimeric antigen receptors (CARs) to precisely target and eradicate cancer cells. With a robust and diverse pipeline of candidates across multiple stages of clinical development, coupled with strategic partnerships, Cellectis is well-positioned to address significant unmet medical needs in oncology and enhance patient outcomes in cancer treatment.

WTO
+19.50%
$0.02
LPTX
+368.57%
$2.05
ASBP
+1.04%
$0.10
VINE
+1.80%
$0.40
AMZE
+1.80%
$0.40
EPWK
+16.62%
$0.04
VHAI
+33.33%
$0.00
NVDA
+1.77%
$190.17
ONDS
+9.45%
$7.18
IVVD
+32.76%
$2.35
BYND
+6.93%
$1.08
ASST
-6.08%
$1.08
CHR
+1.67%
$0.04
TSLA
+0.58%
$404.35
PFE
-2.83%
$25.06
SOFI
-2.00%
$27.82
PLUG
-9.83%
$2.24
BITF
-0.76%
$2.58
NVVE
-45.37%
$0.25
ACHR
-1.00%
$7.88
ETHD
+1.75%
$5.23
INTC
-1.08%
$35.52
RGTI
+1.11%
$25.48
F
-0.67%
$13.19
AXDX
-61.36%
$0.03
PLTR
+1.08%
$174.01
RIVN
-7.80%
$15.11
TLRY
-4.42%
$1.08
CIFR
-3.81%
$14.36
SNAP
-0.11%
$8.57
WULF
-5.90%
$10.99
NIO
-1.28%
$6.16
WBD
+4.01%
$23.03
CRWV
-1.25%
$77.36
QBTS
+0.94%
$23.61
IONZ
-8.28%
$5.20
ADAP
-15.14%
$0.05
DNN
-0.40%
$2.48
BMNR
-5.93%
$34.40
DVLT
+18.83%
$1.83
IREN
-4.68%
$46.37
MARA
-6.18%
$11.99
AMD
-0.46%
$246.81
AAPL
-0.19%
$272.41
DFLI
+4.85%
$0.81
MKDW
-18.20%
$0.16
APLD
+2.55%
$23.65
APLT
-19.14%
$0.21
CLSK
-8.51%
$10.96
GRAB
-2.34%
$5.41
CAN
-8.04%
$0.89
RMBL
+60.50%
$3.21
AMZN
-1.21%
$234.69
LNW
-3.71%
$86.22
CSCO
+0.80%
$78.00
ADD
-25.47%
$0.05
QUBT
+5.68%
$10.60
CRCL
-0.54%
$81.89
T
-0.62%
$25.59
SMCI
+3.79%
$36.42
MU
+4.16%
$246.83
ORCL
+2.42%
$222.85
BTG
0.00%
$4.10
SRM
+53.27%
$10.30
KVUE
-0.65%
$16.66
BABA
-3.77%
$153.80
AAL
-2.37%
$12.76
BBD
+0.54%
$3.68
BAC
-0.49%
$52.61
HOOD
+0.79%
$122.50
NBIS
-5.74%
$83.54
GPUS
-7.60%
$0.27
RIOT
+0.50%
$13.95
GOOGL
-0.77%
$276.41
HIMS
+2.57%
$36.98
RXRX
-4.38%
$4.14
NOK
-0.73%
$6.73
JD
-4.55%
$29.31
PLTZ
-2.27%
$6.88
PLTD
-1.01%
$6.84
HPE
-0.43%
$22.83
QS
-1.03%
$13.43
BTBT
-4.36%
$2.41
IONQ
+3.92%
$47.18
VZ
-0.12%
$41.06
RIG
0.00%
$4.01
WLGS
-5.57%
$0.04
MSFT
+1.36%
$510.18
SOUN
-0.40%
$12.17
MTSR
-0.35%
$70.50
XPON
-8.66%
$1.16
XPEV
-5.19%
$25.01
BURU
-2.77%
$0.24
ABEV
+1.19%
$2.55
BTE
+0.63%
$3.16
SMR
-3.02%
$22.45
RGTZ
-2.55%
$27.42
DEFT
-15.17%
$1.23
VALE
-0.64%
$12.30
EOSE
-9.24%
$13.80
WTO
+19.50%
$0.02
LPTX
+368.57%
$2.05
ASBP
+1.04%
$0.10
VINE
+1.80%
$0.40
AMZE
+1.80%
$0.40
EPWK
+16.62%
$0.04
VHAI
+33.33%
$0.00
NVDA
+1.77%
$190.17
ONDS
+9.45%
$7.18
IVVD
+32.76%
$2.35
BYND
+6.93%
$1.08
ASST
-6.08%
$1.08
CHR
+1.67%
$0.04
TSLA
+0.58%
$404.35
PFE
-2.83%
$25.06
SOFI
-2.00%
$27.82
PLUG
-9.83%
$2.24
BITF
-0.76%
$2.58
NVVE
-45.37%
$0.25
ACHR
-1.00%
$7.88
ETHD
+1.75%
$5.23
INTC
-1.08%
$35.52
RGTI
+1.11%
$25.48
F
-0.67%
$13.19
AXDX
-61.36%
$0.03
PLTR
+1.08%
$174.01
RIVN
-7.80%
$15.11
TLRY
-4.42%
$1.08
CIFR
-3.81%
$14.36
SNAP
-0.11%
$8.57
WULF
-5.90%
$10.99
NIO
-1.28%
$6.16
WBD
+4.01%
$23.03
CRWV
-1.25%
$77.36
QBTS
+0.94%
$23.61
IONZ
-8.28%
$5.20
ADAP
-15.14%
$0.05
DNN
-0.40%
$2.48
BMNR
-5.93%
$34.40
DVLT
+18.83%
$1.83
IREN
-4.68%
$46.37
MARA
-6.18%
$11.99
AMD
-0.46%
$246.81
AAPL
-0.19%
$272.41
DFLI
+4.85%
$0.81
MKDW
-18.20%
$0.16
APLD
+2.55%
$23.65
APLT
-19.14%
$0.21
CLSK
-8.51%
$10.96
GRAB
-2.34%
$5.41
CAN
-8.04%
$0.89
RMBL
+60.50%
$3.21
AMZN
-1.21%
$234.69
LNW
-3.71%
$86.22
CSCO
+0.80%
$78.00
ADD
-25.47%
$0.05
QUBT
+5.68%
$10.60
CRCL
-0.54%
$81.89
T
-0.62%
$25.59
SMCI
+3.79%
$36.42
MU
+4.16%
$246.83
ORCL
+2.42%
$222.85
BTG
0.00%
$4.10
SRM
+53.27%
$10.30
KVUE
-0.65%
$16.66
BABA
-3.77%
$153.80
AAL
-2.37%
$12.76
BBD
+0.54%
$3.68
BAC
-0.49%
$52.61
HOOD
+0.79%
$122.50
NBIS
-5.74%
$83.54
GPUS
-7.60%
$0.27
RIOT
+0.50%
$13.95
GOOGL
-0.77%
$276.41
HIMS
+2.57%
$36.98
RXRX
-4.38%
$4.14
NOK
-0.73%
$6.73
JD
-4.55%
$29.31
PLTZ
-2.27%
$6.88
PLTD
-1.01%
$6.84
HPE
-0.43%
$22.83
QS
-1.03%
$13.43
BTBT
-4.36%
$2.41
IONQ
+3.92%
$47.18
VZ
-0.12%
$41.06
RIG
0.00%
$4.01
WLGS
-5.57%
$0.04
MSFT
+1.36%
$510.18
SOUN
-0.40%
$12.17
MTSR
-0.35%
$70.50
XPON
-8.66%
$1.16
XPEV
-5.19%
$25.01
BURU
-2.77%
$0.24
ABEV
+1.19%
$2.55
BTE
+0.63%
$3.16
SMR
-3.02%
$22.45
RGTZ
-2.55%
$27.42
DEFT
-15.17%
$1.23
VALE
-0.64%
$12.30
EOSE
-9.24%
$13.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.